Laboratory of Tumor Immunology, LIFE Center, LMU Klinikum, University Munich, Germany.
Department of Urology, LMU Klinikum, University Munich, Germany.
Biomed Res Int. 2021 Feb 4;2021:8851035. doi: 10.1155/2021/8851035. eCollection 2021.
It has been shown that miR-192 is abnormally expressed in a variety of cancer types and participates in different kinds of signaling pathways. The role of miR-192 in the diagnosis and prognosis of cancer has not been verified. This article is aimed at exploring the diagnostic and prognostic value of miR-192 through a systematic review and meta-analysis.
A systematic search was performed through PubMed, Embase, Web of Science, and Cochrane Library databases up to June 16, 2020. A total of 16 studies were enrolled in the meta-analyses, of which 11 articles were used for diagnostic meta-analysis and 5 articles were used for prognostic meta-analysis. The values of sensitivity and specificity using miR-192 expression as a diagnostic tool were pooled in the diagnostic meta-analysis. The hazard ratios (HRs) of overall survival (OS) with 95 confidence intervals (CIs) were extracted from the studies, and pooled HRs were evaluated in the prognostic meta-analysis. Eleven studies including 667 cancer patients and 514 controls met the eligibility criteria for the diagnostic meta-analysis. Five studies including 166 patients with high miR-192 expression and 236 patients with low miR-192 expression met the eligibility criteria for the prognostic meta-analysis.
The overall diagnostic accuracy was as follows: sensitivity 0.79 (95%CI = 0.75-0.82), specificity 0.74 (95%CI = 0.64-0.82), positive likelihood ratio 3.03 (95%CI = 2.11-4.34), negative likelihood ratio 0.29 (95%CI = 0.23-0.37), diagnostic odds ratio 10.50 (95%CI = 5.89-18.73), and area under the curve ratio (AUC) 0.82 (95%CI = 0.78-0.85). The overall prognostic analysis showed that high expression of miR-192 in patients was associated with positive survival (HR = 0.62, 95%CI : 0.41-0.93, = 0.020).
Our results revealed that miR-192 was a potential biomarker with good sensitivity and specificity in cancers. Moreover, highly expressed miR-192 predicted a good prognosis for patients.
已经证实 miR-192 在多种癌症类型中异常表达，并参与不同的信号通路。miR-192 在癌症的诊断和预后中的作用尚未得到验证。本文旨在通过系统评价和荟萃分析探讨 miR-192 的诊断和预后价值。
通过 PubMed、Embase、Web of Science 和 Cochrane Library 数据库系统检索，截至 2020 年 6 月 16 日。荟萃分析共纳入 16 项研究，其中 11 项用于诊断荟萃分析，5 项用于预后荟萃分析。使用 miR-192 表达作为诊断工具的诊断荟萃分析中，合并了敏感性和特异性的值。从研究中提取总生存期（OS）的风险比（HR）及其 95%置信区间（CI），并在预后荟萃分析中评估合并 HR。符合诊断荟萃分析纳入标准的研究共 11 项，包括 667 例癌症患者和 514 例对照。符合预后荟萃分析纳入标准的研究共 5 项，包括 166 例 miR-192 高表达患者和 236 例 miR-192 低表达患者。
总的诊断准确性如下：敏感性 0.79（95%CI = 0.75-0.82），特异性 0.74（95%CI = 0.64-0.82），阳性似然比 3.03（95%CI = 2.11-4.34），阴性似然比 0.29（95%CI = 0.23-0.37），诊断比值比 10.50（95%CI = 5.89-18.73），曲线下面积比（AUC）0.82（95%CI = 0.78-0.85）。总的预后分析显示，患者中 miR-192 的高表达与生存呈正相关（HR = 0.62，95%CI：0.41-0.93， = 0.020）。
我们的结果表明，miR-192 是一种潜在的癌症诊断标志物，具有良好的敏感性和特异性。此外，高表达的 miR-192 预示着患者的预后良好。
